These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 23081985)

  • 1. Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy.
    Makihara RA; Makino Y; Yamamoto N; Yokote N; Nokihara H; Sekine I; Ohe Y; Tamura T; Yamamoto H
    Jpn J Clin Oncol; 2012 Dec; 42(12):1187-91. PubMed ID: 23081985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer.
    Watanabe H; Ikesue H; Oshiro M; Nagata K; Mishima K; Takada A; Suetsugu K; Sueyasu M; Egashira N; Harada T; Takayama K; Nakanishi Y; Oishi R
    Chemotherapy; 2012; 58(6):419-25. PubMed ID: 23295219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
    Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
    Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.
    Takakuwa O; Oguri T; Uemura T; Kunii E; Nakao M; Hijikata H; Kawaguchi Y; Ohkubo H; Takemura M; Maeno K; Niimi A
    Anticancer Res; 2014 Jul; 34(7):3517-22. PubMed ID: 24982363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
    Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
    Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of adverse events of amrubicin hydrochloride for pretreated lung cancer patients].
    Takase M; Maruoka H; Maeda R; Shibata K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1789-92. PubMed ID: 18030011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens.
    Igawa S; Takahashi T; Nakamura Y; Tsuya A; Ono A; Shukuya T; Murakami H; Endo M; Yamamoto N
    Anticancer Res; 2008; 28(6B):3855-8. PubMed ID: 19192640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].
    Nitta T; Yamasaki M; Kajihara T; Mito A; Awaya H; Ikegami Y; Arita K
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1045-9. PubMed ID: 20567105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
    Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
    Kitagawa C; Saka H; Kajikawa S; Mori K; Oki M; Suzuki R
    Cancer Chemother Pharmacol; 2012 May; 69(5):1379-85. PubMed ID: 22237957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
    Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
    J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
    Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
    J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
    Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer.
    Ikeda J; Maruyama R; Okamoto T; Shoji F; Wataya H; Ichinose Y
    Jpn J Clin Oncol; 2006 Jan; 36(1):12-6. PubMed ID: 16418184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
    Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
    Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
    Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
    Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
    Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Two cases of severe myelosuppression from amrubicin in previously-treated small cell lung cancer].
    Suzuki H; Sasada S; Matsuda Y; Otani Y; Morishita N; Kobayashi M; Okamoto N; Hirashima T; Matsui K; Kawase I
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):491-3. PubMed ID: 18347402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term amrubicin chemotherapy for small-cell lung cancer.
    Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Kawase I
    Anticancer Res; 2012 Apr; 32(4):1423-7. PubMed ID: 22493380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Our clinical experiences of amrubicin hydrochloride monotherapy in extensive-disease small cell lung cancer].
    Kawakami M; Ohno S; Tsujita A; Hosono T; Kobayashi A; Yamasawa H; Bando M; Sugiyama Y
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):273-6. PubMed ID: 18281764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.